GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (NAS:YTEN) » Definitions » ROC (Joel Greenblatt) %

Yield10 Bioscience (Yield10 Bioscience) ROC (Joel Greenblatt) % : -569.15% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Yield10 Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -569.15%.

The historical rank and industry rank for Yield10 Bioscience's ROC (Joel Greenblatt) % or its related term are showing as below:

YTEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4445.28   Med: -508.13   Max: -163.19
Current: -581.99

During the past 13 years, Yield10 Bioscience's highest ROC (Joel Greenblatt) % was -163.19%. The lowest was -4445.28%. And the median was -508.13%.

YTEN's ROC (Joel Greenblatt) % is ranked worse than
97.99% of 249 companies
in the Agriculture industry
Industry Median: 9.45 vs YTEN: -581.99

Yield10 Bioscience's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -24.90% per year.


Yield10 Bioscience ROC (Joel Greenblatt) % Historical Data

The historical data trend for Yield10 Bioscience's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience ROC (Joel Greenblatt) % Chart

Yield10 Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -163.19 -239.72 -340.03 -449.87 -584.04

Yield10 Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -454.55 -572.72 -576.80 -607.42 -569.15

Competitive Comparison of Yield10 Bioscience's ROC (Joel Greenblatt) %

For the Agricultural Inputs subindustry, Yield10 Bioscience's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yield10 Bioscience's ROC (Joel Greenblatt) % Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's ROC (Joel Greenblatt) % falls into.



Yield10 Bioscience ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.545) - (1.852 + 0 + 0.417)
=-1.724

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.332) - (3.082 + 0 + 0.103)
=-2.853

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Yield10 Bioscience for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.988/( ( (2.363 + max(-1.724, 0)) + (2.201 + max(-2.853, 0)) )/ 2 )
=-12.988/( ( 2.363 + 2.201 )/ 2 )
=-12.988/2.282
=-569.15 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yield10 Bioscience  (NAS:YTEN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Yield10 Bioscience ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yield10 Bioscience (Yield10 Bioscience) Business Description

Traded in Other Exchanges
Address
19 Presidential Way, Woburn, MA, USA, 01801
Yield10 Bioscience Inc is an agricultural bioscience company. It focuses on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. The company uses two proprietary advanced biotechnology trait gene discovery platforms to improve fundamental crop yield through enhanced photosynthetic carbon capture and increased carbon utilization efficiency to increase seed yield. Having developed various crops, such as Camelina, canola, soybean, and corn, the firm concentrates to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton director 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser officer: VP Fin and CAO
Lynne H Brum officer: VP Planning and Comms 21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell officer: VP Research & CSO C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey director C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples director, officer: Pres & CEO C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin director 21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully 10 percent owner C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038

Yield10 Bioscience (Yield10 Bioscience) Headlines

From GuruFocus